PIK3CB and cancer: For example, preclinical studies of the pan-Class I PI3K inhibitor pictilisib demonstrated that greater than 90% inhibition of AKT phosphorylation over several hours is required for 50% reduction in the number of proliferating cancer cells in vitro and subsequent growth arrest in tumour xenografts [20, 55].